Efficacy of cyclosporine eyedrop 0.1% in the treatment of dry eye in primary sjogren's syndrome: A prospective Indian study
Objectives: The objective of this study was to evaluate the efficacy and safety of 0.1% cyclosporine A (CsA) eyedrop in patients having primary Sjogren's syndrome (SS) in India. Methods: A prospective consecutive case series of total 20 patients with moderate-to-severe dry eyes were treated wit...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-01-01
|
| Series: | Indian Journal of Rheumatology |
| Subjects: | |
| Online Access: | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2023;volume=18;issue=1;spage=74;epage=77;aulast=Sabhapandit |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563525321490432 |
|---|---|
| author | Swapnali Sabhapandit Madhuri Radhakrishna Shireesha Anumula Arifa Shaik Solomon Perumalla Sahithi Venapally |
| author_facet | Swapnali Sabhapandit Madhuri Radhakrishna Shireesha Anumula Arifa Shaik Solomon Perumalla Sahithi Venapally |
| author_sort | Swapnali Sabhapandit |
| collection | DOAJ |
| description | Objectives: The objective of this study was to evaluate the efficacy and safety of 0.1% cyclosporine A (CsA) eyedrop in patients having primary Sjogren's syndrome (SS) in India.
Methods: A prospective consecutive case series of total 20 patients with moderate-to-severe dry eyes were treated with 0.1% CsA eyedrop twice daily along with lubricating eyedrop for 3 months. Efficacy measures included ocular staining score (OSS), van Bijsterveld score (VBS), and Schirmer's score of each eye based on the 2016 ACR-EULAR classification. Subjective improvement was also recorded at the final visit. Any adverse effects were noted.
Results: Treatment with 0.1% CsA eyedrop showed a statistically significant improvement at 3 months for both OSS and VBS in each eye of study patients. A similar improvement in Schirmer's score was noted in each eye of the subjects. Subjective improvement of ocular sicca symptoms was also demonstrated. There was excellent compliance to therapy. The 0.1% CsA formulation did not show any topical or systemic side effects in any patient.
Conclusion: The 0.1% ophthalmic preparation of CsA is safe and effective in the management of moderate-to-severe dry eyes in patients with primary SS in this pilot study in Indian patients. |
| format | Article |
| id | doaj-art-d34a048155724492b3d9316276a2b9c8 |
| institution | Kabale University |
| issn | 0973-3698 0973-3701 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Indian Journal of Rheumatology |
| spelling | doaj-art-d34a048155724492b3d9316276a2b9c82025-02-03T01:13:27ZengSAGE PublishingIndian Journal of Rheumatology0973-36980973-37012023-01-01181747710.4103/injr.injr_49_22Efficacy of cyclosporine eyedrop 0.1% in the treatment of dry eye in primary sjogren's syndrome: A prospective Indian studySwapnali SabhapanditMadhuri RadhakrishnaShireesha AnumulaArifa ShaikSolomon PerumallaSahithi VenapallyObjectives: The objective of this study was to evaluate the efficacy and safety of 0.1% cyclosporine A (CsA) eyedrop in patients having primary Sjogren's syndrome (SS) in India. Methods: A prospective consecutive case series of total 20 patients with moderate-to-severe dry eyes were treated with 0.1% CsA eyedrop twice daily along with lubricating eyedrop for 3 months. Efficacy measures included ocular staining score (OSS), van Bijsterveld score (VBS), and Schirmer's score of each eye based on the 2016 ACR-EULAR classification. Subjective improvement was also recorded at the final visit. Any adverse effects were noted. Results: Treatment with 0.1% CsA eyedrop showed a statistically significant improvement at 3 months for both OSS and VBS in each eye of study patients. A similar improvement in Schirmer's score was noted in each eye of the subjects. Subjective improvement of ocular sicca symptoms was also demonstrated. There was excellent compliance to therapy. The 0.1% CsA formulation did not show any topical or systemic side effects in any patient. Conclusion: The 0.1% ophthalmic preparation of CsA is safe and effective in the management of moderate-to-severe dry eyes in patients with primary SS in this pilot study in Indian patients.http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2023;volume=18;issue=1;spage=74;epage=77;aulast=Sabhapanditdry eyesschirmer'socular staining scorecyclosporine 0.1% |
| spellingShingle | Swapnali Sabhapandit Madhuri Radhakrishna Shireesha Anumula Arifa Shaik Solomon Perumalla Sahithi Venapally Efficacy of cyclosporine eyedrop 0.1% in the treatment of dry eye in primary sjogren's syndrome: A prospective Indian study Indian Journal of Rheumatology dry eyes schirmer's ocular staining score cyclosporine 0.1% |
| title | Efficacy of cyclosporine eyedrop 0.1% in the treatment of dry eye in primary sjogren's syndrome: A prospective Indian study |
| title_full | Efficacy of cyclosporine eyedrop 0.1% in the treatment of dry eye in primary sjogren's syndrome: A prospective Indian study |
| title_fullStr | Efficacy of cyclosporine eyedrop 0.1% in the treatment of dry eye in primary sjogren's syndrome: A prospective Indian study |
| title_full_unstemmed | Efficacy of cyclosporine eyedrop 0.1% in the treatment of dry eye in primary sjogren's syndrome: A prospective Indian study |
| title_short | Efficacy of cyclosporine eyedrop 0.1% in the treatment of dry eye in primary sjogren's syndrome: A prospective Indian study |
| title_sort | efficacy of cyclosporine eyedrop 0 1 in the treatment of dry eye in primary sjogren s syndrome a prospective indian study |
| topic | dry eyes schirmer's ocular staining score cyclosporine 0.1% |
| url | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2023;volume=18;issue=1;spage=74;epage=77;aulast=Sabhapandit |
| work_keys_str_mv | AT swapnalisabhapandit efficacyofcyclosporineeyedrop01inthetreatmentofdryeyeinprimarysjogrenssyndromeaprospectiveindianstudy AT madhuriradhakrishna efficacyofcyclosporineeyedrop01inthetreatmentofdryeyeinprimarysjogrenssyndromeaprospectiveindianstudy AT shireeshaanumula efficacyofcyclosporineeyedrop01inthetreatmentofdryeyeinprimarysjogrenssyndromeaprospectiveindianstudy AT arifashaik efficacyofcyclosporineeyedrop01inthetreatmentofdryeyeinprimarysjogrenssyndromeaprospectiveindianstudy AT solomonperumalla efficacyofcyclosporineeyedrop01inthetreatmentofdryeyeinprimarysjogrenssyndromeaprospectiveindianstudy AT sahithivenapally efficacyofcyclosporineeyedrop01inthetreatmentofdryeyeinprimarysjogrenssyndromeaprospectiveindianstudy |